Bli medlem
Bli medlem

Du är här

2016-04-13

AREVA Med: AREVA Med Inaugurates Second Lead-212 Production Facility

Harry LaRosiliere, mayor of Plano; Patrick Bourdet, AREVA Med CEO photo
credit: Jim Herndon

PLANO, Texas, April 13, 2016 (GLOBE NEWSWIRE) -- AREVA Med has launched
operations at its second high-purity lead-212 (212Pb) production facility
located in Plano, Texas. Known as the DDPU (Domestic Distribution and
Purification Unit), this facility was officially opened today in the presence
of local elected officials, AREVA Med Scientific Advisory Committee, as well
as AREVA Group and AREVA Med executives and teams from both the U.S. and
France.

A photo accompanying this release is available at
http://www.globenewswire.com/NewsRoom/AttachmentNg/bccb050d-dfc0-46c3-99...

Thanks to its unique characteristics, lead-212 is used in targeted alpha
therapy (TAT), in an increasing number of promising and innovative studies to
target cancer cells, while limiting the impact on nearby healthy cells.

In a centralized modular plant, the DDPU will hold all AREVA Med's U.S.
activities and those of its subsidiary Macrocyclics, the global leader in the
design and manufacturing of chelating agents for nuclear medicine. With brand
new equipment, this state-of-the-art facility is a unique opportunity for
AREVA Med to expand the range and increase the quality of products and
services for its American partners and customers. Thanks to this increased
production capacities, AREVA Med will accelerate the development of
innovative Targeted Alpha Therapies using lead-212 to combat cancer.

Harry LaRosiliere, the mayor of Plano, declared: "It is always a great day
when we can welcome to the City of Plano a U.S.
Headquarters and international company such as AREVA Med, which does
invaluable work in the field of cancer research. We look forward to their
success and future expansion as they continue to develop innovative cancer
therapies."

Patrick Bourdet, AREVA Med's CEO added:"Our new modular and unique U.S. plant
will allow us to quickly expand our
cancer therapy pipeline and increase collaboration within the entire
continent."

More information at www.arevamed.com, @AREVAmed

More about AREVA Med

AREVA Med is the AREVA Group medical subsidiary formed in 2009 to develop new
therapies to fight cancer. AREVA Med has developed a unique process to
extract lead-212 (212Pb), a rare metal used in targeted alpha therapy (TAT),
a novel approach which targets and destroys cancer cells, while limiting the
impact on nearby healthy cells. AREVA Med collaborates with world-renowned
scientific partners, and formed a strategic global alliance with Roche in
2012, to create a new advanced alpha radioimmunotherapy platform.

Press Contacts

AREVA Med
Alison Tise
(301) 841-1673
Alison.Tise@areva.com
@AREVAmed

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: AREVA Med via Globenewswire

HUG#2003419

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.